Pebrilzo Wins FDA Approval as a Second Perjeta Biosimilar—but U.S. Patients May Have to Wait Until Late 2028
The biosimilar expands Biocon’s oncology portfolio and offers a new treatment option for patients with HER2-positive breast cancer.
5 Articles
5 Articles
Pebrilzo wins FDA approval as a second Perjeta biosimilar—but U.S. patients may have to wait until late 2028
The FDA approved Biocon's Pebrilzo, a second Perjeta biosimilar for adults with HER2-positive breast cancer. It will not launch in the United States before the third quarter of 2028.
FDA Approves Pertuzumab Biosimilar in HER2+ Breast Cancer
The FDA has approved pertuzumab-qcay, a biosimilar of the reference product Perjeta, in HER2-positive breast cancer, based on a data package that showed no meaningful differences in quality, safety, efficacy, or immunogenicity.
Biocon Wins USFDA Nod for Breast Cancer Drug Pebrilzo
Biocon secured US FDA approval for Pebrilzo, a biosimilar of breast cancer drug Perjeta, marking its fifth oncology biosimilar in the US. Biocon Limited told exchanges on Monday, 16 November, that the regulator had cleared the injection, known generically as pertuzumab-qcay. A biosimilar is a close copy of an existing...
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium







